Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer, effective August 3, 2026. His employment agreement includes an annual base salary of $545,000, eligibility for an annual bonus up to 40% of his base salary, and equity awards valued at $2,100,000. The company also provided updates on its clinical pipeline, expecting to initiate the CRB-701 registrational study in 2L OPSCC and report topline findings from the CRB-913 obesity study in late summer 2026.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in solid tumor drug development, including his work on the antibody drug conjugate TIVDAK®. The company also highlighted upcoming milestones, including the planned initiation of the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma this summer, and data readouts for CRB-913 in obesity and CRB-701 in 1L OPSCC.

Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for CRB-701, a Nectin-4 targeted ADC, demonstrating robust activity in second-line oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. The data, to be presented at ASCO 2026, showed confirmed objective response rates of 42.9% in OPSCC and 34.4% in cervical cancer at the 3.6 mg/kg dose, with favorable safety and low discontinuation rates. The company also reported positive early weight loss data for CRB-913 in obesity and confirmed broad FDA alignment for registrational studies for CRB-701 in both cancer indications, with the OPSCC study expected to start in summer 2026.

Corbus Pharmaceuticals reported updated positive Phase 1/2 clinical data for CRB-701, a Nectin-4 targeted ADC, in second-line oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. The data showed robust activity and a favorable safety profile, affirming the company's strategy. Based on these results, Corbus is on track to initiate a registrational study for CRB-701 in 2L OPSCC in summer 2026, with broad FDA alignment on the trial design. Similar FDA alignment was reached for a 2L cervical cancer study.

Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Nishant Saxena as its first Chief Business Officer, signaling a strategic move towards commercialization and value creation. The company also revealed plans to host a conference call and webcast on May 26 to discuss updated Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer, which will be presented at the 2026 ASCO Annual Meeting. Additionally, Corbus anticipates two key pipeline milestones this summer: the initiation of a registrational study for CRB-701 in second-line HNSCC and the completion of the CANYON-1 Phase 1b study for CRB-913 in obesity.

Corbus Pharmaceuticals Holdings, Inc. appointed Brent Pfeiffenberger, a seasoned pharma industry veteran, to its Board of Directors, expanding the board to seven members. Dr. Pfeiffenberger brings extensive experience from leadership roles at Century Therapeutics, Neogene Therapeutics, and Bristol-Myers Squibb, particularly in oncology. Concurrently, stockholders approved an amendment to the 2024 Equity Compensation Plan, increasing the authorized shares for issuance by 3,000,000 to a total of 5,000,000 shares. The company anticipates important data readouts for its CRB-701 and CRB-913 clinical programs this summer, alongside the expected initiation of a registrational study for CRB-701.

Corbus Pharmaceuticals Holdings, Inc. announced that its Chief Executive Officer, Yuval Cohen, Ph.D., will present a corporate overview and participate in investor meetings at two upcoming healthcare conferences. He is scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and at the Jefferies Global Healthcare Conference on June 4, 2026. The company is focused on developing new therapies in oncology and obesity.

Corbus Pharmaceuticals reported a net loss of $23.0 million for Q1 2026, a significant increase from $17.0 million in Q1 2025, driven by a 27% rise in research and development expenses. The company's cash and investments totaled $138.2 million as of March 31, 2026, which is expected to fund operations for at least twelve months. Subsequent to the quarter, Corbus sold additional common stock for $8.9 million and made a $10.0 million milestone payment for its CRB-701 program.

Corbus Pharmaceuticals reported a net loss of $23.0 million for Q1 2026, an increase from $17.0 million in Q1 2025, with operating expenses rising to $24.3 million due to increased clinical development. Despite the financial loss, the company announced significant progress in its clinical programs, including broad FDA alignment for CRB-701's registration path in HNSCC and cervical cancer, with a registrational study expected to start this summer. Additionally, enrollment was completed for the CRB-913 CANYON-1 study for obesity, with topline data anticipated this summer.

Corbus Pharmaceuticals announced significant progress in its oncology and obesity programs. The company reached broad alignment with the FDA on the registration path for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer, with updated data to be presented at ASCO 2026 and a registrational study for 2L HNSCC starting this summer. Additionally, Corbus completed enrollment for its CRB-913 CANYON-1 Phase 1b study for obesity, with topline data anticipated this summer. For Q1 2026, the company reported a net loss of $23.0 million, an increase from $17.0 million in Q1 2025, primarily due to higher clinical development expenses. Corbus maintains a strong cash position of $138.2 million, expected to fund operations into 2028.